Levetiracetam Tablet, Film Coated, Extended Release
Product Images NDC 60505-3518

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 60505-3518). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Apotex Corp., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Fig1.jpg (Fig1)

A bar graph showing the percentage of patients for three groups: Placebo (7.4%), Immediate-release levetiracetam tablets 1000 mg/day (37.1%), and Immediate-release levetiracetam tablets 3000 mg/day (39.6%). The graph indicates statistical significance versus placebo for the immediate-release levetiracetam groups.*

FDA Label Image

Fig2.jpg (Fig2)

A bar graph comparing the percentage of patients across three groups: placebo, immediate-release levetiracetam tablets 1000 mg/day, and immediate-release levetiracetam tablets 2000 mg/day. The graph shows increasing percentages of patients with 6.3% for placebo, 20.8% for 1000 mg/day, and 35.2% for 2000 mg/day, with statistical significance noted for the active treatment groups versus placebo.*

FDA Label Image

Fig3.jpg (Fig3)

Bar chart comparing the percentage of patients experiencing a certain outcome between placebo (14.4%, N=104) and immediate-release levetiracetam tablets 3000 mg/day (39.4%, N=180). The chart notes statistical significance for the levetiracetam group versus placebo.*

FDA Label Image

Fig4.jpg (Fig4)

A bar chart comparing the percentage of patients with a specific outcome between placebo and immediate-release levetiracetam tablets. The placebo group (N=97) shows about 19.6%, while the immediate-release levetiracetam group (N=101) shows about 44.6%, with a note indicating statistical significance versus placebo.*

FDA Label Image

Lbl1000mg60s.jpg (Lbl1000mg60s)

Label for Levetiracetam Extended-Release Tablets, USP, 1,000 mg strength, film-coated, oral tablets. The label indicates a package count of 60 tablets and includes storage instructions and dispensing guidelines. Manufactured by Apotex Inc. and labeled for Apotex Corp. The label features the NDC number 60505-3518-6 and includes a barcode.*

FDA Label Image

Lbl500mg60s.jpg (Lbl500mg60s)

Label for Levetiracetam Extended-Release Tablets, USP 500 mg by Apotex Corp. The label indicates a package of 60 film-coated extended-release tablets, with once daily dosing. Storage instructions and dispensing warnings are included, along with manufacturer and labeler information. The NDC code 60505-3280-6 is visible on the label.*

FDA Label Image

Lbl750mg60s.jpg (Lbl750mg60s)

Label of Levetiracetam Extended-Release Tablets, USP 750 mg by Apotex Corp. The label indicates a package of 60 film-coated extended-release tablets for oral use. It includes storage instructions, dosage strength, and manufacturer information, along with a barcode and NDC number 60505-3517-6.*

FDA Label Image

Levetiracetamxr-01 (Levetiracetam Xr 01)

Chemical structure of levetiracetam, showing its molecular arrangement with functional groups including a pyrrolidone ring and an aminoacetamide side chain.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.